Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Notes Payables (2021 - 2023)

Historic Notes Payables for Avalo Therapeutics (AVTX) over the last 3 years, with Q2 2023 value amounting to $14.1 million.

  • Avalo Therapeutics' Notes Payables changed N/A to $14.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $14.1 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2022, which is N/A changed from last year.
  • Avalo Therapeutics' Notes Payables amounted to $14.1 million in Q2 2023.
  • Avalo Therapeutics' 5-year Notes Payables high stood at $33.2 million for Q1 2022, and its period low was $2.6 million during Q3 2022.
  • For the 3-year period, Avalo Therapeutics' Notes Payables averaged around $16.4 million, with its median value being $14.1 million (2023).
  • As far as peak fluctuations go, Avalo Therapeutics' Notes Payables plummeted by 9210.66% in 2022, and later crashed by 7198.57% in 2023.
  • Quarter analysis of 3 years shows Avalo Therapeutics' Notes Payables stood at $32.5 million in 2021, then crashed by 81.74% to $5.9 million in 2022, then soared by 138.03% to $14.1 million in 2023.
  • Its Notes Payables stands at $14.1 million for Q2 2023, versus $9.3 million for Q1 2023 and $5.9 million for Q4 2022.